
|Videos|March 15, 2016
To What Extent Should People Have Access to Naloxone?
Jeffrey Fudin, PharmD, DAAPM, FCCP, FASHP, outlines his pros and cons for expanded access to naloxone.
Advertisement
Jeffrey Fudin, PharmD, DAAPM, FCCP, FASHP, outlines his pros and cons for expanded access to naloxone.
This video was recorded at APhA's 2016 Annual Meeting and Exposition in Baltimore, Maryland.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Targeting CSF1R in TGCT: Evaluating the Evidence and Empowering Pharmacist-Led Care
2
Early Recognition and Routine Discussion: Improving Outcomes in Tardive Dyskinesia
3
Meet the FDA’s Newly Approved OTC Sunscreen Ingredient: Bemotrizinol
4
Do GLP-1 Receptor Agonists Increase the Risk of Smell and Taste Disturbances?
5










































































































